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Betulinic acid (BA) was demonstrated to be a very promising anticancer agent against
various tumor cell lines such as breast, colon, lung, and brain. Despite its strong
cytotoxic effect, betulinic acid exhibits low water solubility, feature that is reflected
in its poor bioavailability. To overcome these drawbacks, numerous strategies were
conducted to improve its physicochemical and pharmacokinetic profile, among which
cocrystalization emerged as a promising approach. Thus, our work consisted in
obtaining slowly grown cocrystals of BA and ascorbic acid (BA+VitC) in isopropyl
alcohol obtained in a hydrothermal experiment. The newly formed cocrystals were
characterized by physico-chemical methods such asSEM, DSC, XRPD, and FT-IR
spectroscopy demonstrating BA+VitC cocrystal formation while their antioxidant activity
revealed an additive antioxidant effect. To investigate the biological effect, BA+VitC
cocrystals were tested on HaCat (immortalized human keratinocytes), B164A5 and
B16F0 (murine melanoma), MCF7 and MDA-MB-231 (human breast cancer), and HeLa
(cervical cancer) cell lines. Results of BA upon the tested tumor cell lines, after co-
crystallization with vitamin C, indicated a superior cytotoxic effect with the preservation
of a good selectivity index assumably due to an improved BA water solubility and
consequently an optimized bioavailability.
Keywords: cocrystal, betulinic acid, vitamin C, antioxidant activity, antiproliferative activity
INTRODUCTION
The field of pharmaceutical formulations is similar to a living organism, constantly changing,
and adapting to new therapeutic needs. Numerous newly reported active chemical compounds
exhibit low water solubility and dissolution rate which may correlate to poor bioavailability,
especially via oral administration (Gadade et al., 2016). Among the current options to mitigate
these flaws (Prasad et al., 2012), crystal engineering provides several possibilities to develop
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single- or multi-component alterations of an active compound,
including the synthesis of pharmaceutical cocrystals
(Pathak et al., 2013). Cocrystals are crystalline complexes of
active/neutral compounds that form a unique crystalline lattice
through non-covalent bonds, in particular hydrogen bonds; the
main benefit associated with cocrystallization consists in the
preservation of the intrinsic pharmacological properties of the
active ingredients while the physicochemical profile (i.e., melting
point, solubility, dissolution, etc.) changes (Prasad et al., 2012).
Drug-drug cocrystals represent a promising line of research in
light of the fact that combined therapies are frequently prescribed
for the effective treatment of numerous pathologies (Sekhon,
2012); cocrystals of multiple active compounds might overcome
the drawbacks of conventionally combined drugs.
Betulinic acid [BA, 3β-hydroxy-20(19)-lupan-28-oic acid] is
a pentacyclictriterpene of lupan skeleton with a wide range of
pharmacological activities such as: anti-inflammatory, antitumor
(Faujan et al., 2009), anti-angiogenic (Mukherjee et al., 2004),
anti-viral (Baltina et al., 2003), and antiplasmodial (Ziegler
et al., 2004); its first anticancer effect against melanoma was
reported by Pisha et al. (1995). The antitumor activity of
betulinic acid is currently known to be selectively exerted on
numerous tumor cell lines (breast, colon, lung, brain) mainly by
apoptosis induction (Fulda and Kroemer, 2009). The favorable
therapeutic index suggests betulinic acid as promising antitumor
agent (Pisha et al., 1995). It also possesses significant antioxidant
properties as revealed by Peng et al. (2015).
Betulinic acid is characterized by high hydrophobicity
and limited aqueous solubility leading to poor bioavailability;
therefore, it qualifies as candidate for cocrystallization in order
to achieve superior pharmacokinetic properties.
Ascorbic acid, vitamin C, (2R)-2-[(1S)-1,2-dihydroxyethyl]-
3,4-dihydroxy-2H-furan-5-one (VitC), is a natural highlywater-
soluble vitamin which acts as a potent reducing and antioxidant
agent; its biomedical uses reside in fighting bacterial infections,
in detoxifying reactions, and in the formation of collagen
in fibrous tissue, teeth, bones, connective tissue, skin, and
capillaries. VitC was previously used as cocrystal former for
several nutraceuticals in a patent issued in 2008 for the
purpose of providing improved properties, in particular as
oral formulations (Zaworotko et al., 2008). It also acted
as cocrystal former for several zwitterion structures (i.e.,
sarcosine, nicotinic acid, betaine) leading to cocrystals that
exhibit carboxylate-hydroxyl supramolecular heterosynthons
(based on intermolecular hydrogen bonds) (Kavuru et al., 2010).
Up until recently, a significant number of computational
methods that can predict new cocrystal formation from various
structures have been developed. Such an approach consists in
the determination of molecular electrostatic potential surfaces
(MEPS) for molecular complementarity assessment, as well as
the assessment of potential cocrystal formation based on an
electrostatic model described by intramolecular interactions as a
set of specific contact interaction points (SSIPs) on the molecular
surfaces (Karagianni and Malamatari, 2018).
A synergistic antioxidant effect of betulinic acid and ascorbic
acid mixture was described by Adesanwo et al. (2013) who
suggested the ascorbic acid-mediated chain-breaking electron
transfer to DPPH (2,2-diphenyl-1-picrylhydrazyl) followed by
ascorbic acid regeneration due to proton transfer from betulinic
acid, thus leading to a resonance stabilized betulinic acid
radical (Adesanwo et al., 2013).
This paper is the first approach to obtain and characterize
slowly grown cocrystals of betulinic acid and ascorbic acid,
using as solvent isopropyl alcohol. Given the already reported
significant antioxidant activity of both compounds and that a
Cambridge data base search was made and the a BA+VitC
cocrystal has yet to be reported, we also aimed to assess the
synergistic/additive result of cocrystallization in terms of this
particular biological effect. To the best of our knowledge, no
previous studies of betulinic acid cocrystals were reported. In
addition, the biological in vitro activity of the cocrystals was
tested on both normal and cancer cell lines.
MATERIALS AND METHODS
Materials
Betulinic acid (99%), L-ascorbic acid (99.7–100.5%), 2,2-
diphenyl-1-picrylhydrazyl (DPPH) were purchased from Sigma-
Aldrich, Germany; isopropyl alcohol and ethanol 96% (v/v) from
Chemical Company SA, Iasi, Romania. All substances were used
without further purification.
Gas Phase ab initio DFT Calculations for
BA-VitC Cocrystal Formation
This method is based on the calculation of gas phase MEP
for the proposed structures, followed by the conversion of
local MEP maxima and minima into SSIPs, α and β, that
describe the potential H-bond interaction sites (Musumeci et al.,
2011; Grecu et al., 2013). Structure geometry optimization
and DFT calculations were employed by using the GAMESS
software while MEPS were generated using MacMolPlt and
Avogadro. Geometry optimization and MEP for both structures
were achieved by ab initio gas phase DFT calculations, at
the B3LYP 6-31G(d) level of theory. Local MEP maxima and
minima were converted in SSIPs using the following equations
(Equations 1, 2) (Musumeci et al., 2011);
α =0.0000162MEP2max+0.00962MEPmax (1)
β =0.000146MEP2min−0.00930MEPmin, (2)
where:
MEPmaxand MEPmin represent local maxima and minima
(energy values were given in Hartrees)
Calculated SSIPs were paired for the pure structures and the
cocrystal as follows: the highest α values interact with the highest
β values, the second highest α value interact with the second
highest β and so on. After α/β pairing, the total interaction
site energy for the pure solids and cocrystal was estimated
using Equation (3) (Musumeci et al., 2011). Energy values were
converted from Hartrees into kJ/mol.
E = −
∑
ij
αiβj (3)
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The calculated energy difference between the interaction site
pairing energies of the cocrystal and the two pure forms
(Equation 4) provides a probability measure for a cocrystal
formation (1:1) based on the assumption that within the cocrystal
more favorable interactions will be formed.
1E = Eccry − xEa − yEb (4)
where:
Eccry is the calculated interaction energy of the cocrystal,
Ea and Eb are the calculated interaction energies for the pure
structures, and
x,y represent the molar ratio of the two structures within
the cocrystal.
Synthesis of BA+VitC Cocrystals From
Isopropyl Alcohol
30.3mg BA (MW 456.71 g/mole) and 11.7mg VitC (MW
176.12 g/mole) were solubilized in 1:1 molar ratio using 4ml
isopropyl alcohol. The mixture was heated at 55◦C and then
allowed to cool slowly at room temperature, protected from
light. The formation of the first crystals was recorded after
10 days.
Scanning Electron Microscopy (SEM)
The morphology of the sample was investigated by SEM–
scanning electron microscopy (Hitachi S4700, Hitachi Scientific
Ltd., Tokyo, Japan) at 10 kV. The samples were gold-palladium
coated (90 s) with a sputter coater (Bio-Rad SC 502, VG
Microtech, Uckfield, UK) using an electric potential of 2.0 kV at
10mA for 10min. The air pressure was 1.3–13.0 mPa.
Differential Scanning Calorimetry (DSC)
The thermal response of each product was measured using a
differential scanning calorimeter (Mettler Toledo TG 821e DSC
Mettler Inc., Schwerzenbach, Switzerland). About 3–5mg of
powder was precisely weighed into DSC sample pans which were
hermetically sealed and lid pierced. Samples were measured in
the temperature range of 25–350◦C at a heating rate of 10◦C/min
under constant argon flow of 150 ml/min. Data analysis was
performed using the STARe software.
X-Ray Powder Diffraction (XRPD)
The XRPD measurement was carried out with a BRUKER D8
Advance X-ray powder diffractometer (Bruker AXS GmbH,
Karlsruhe, Germany) with Cu K λI radiation (λ = 1.5406 Å)
and a VÅNTEC-1 detector. The powder samples were loaded in
contact with a plane quartz glass sample slide with an etched
square, and measured. Samples were scanned at 40 kV and
40mA. The angular range was 3–40◦ 2θ, at a step time of 0.1 s and
a step size of 0.007◦. All manipulations, including Kα2-stripping,
background removal, and smoothing of the area under the peaks
of the diffractograms were performed using the DIFFRACTPLUS
EVA software.
Rietveld analysis on the obtained X-ray diffraction pattern,
was carried out using the MAUD software. The refinement
was carried out using available structural crystallographic
information of the two constitutive phases, namely BA and VitC.
Fourier-Transform Infra-Red Spectroscopy
(FTIR)
FTIR spectra were recorded on a JASCO 670+ instrument
after KBr pelleting. The data were collected in 4,000–400 cm−1
spectral range. Spectra were built up after a number of 24
acquisitions for each spectrum, with a resolution of 2 cm−1.
Antioxidant Activity Assay
An amount of cocrystal material was dissolved in 1ml
isopropanol in order to obtain a final concentration of 1.04
mg/ml. The antioxidant activity (AOA) was evaluated by DPPH
radical scavenging assay, which was originally described by Blois
(1958). Briefly, 1 mmol·L−1 solution of DPPH was prepared and
stored at 4◦C, in the dark, and was used as a standard antioxidant
stock solution. A reference solution of 0.167 mmol·L−1ascorbic
acid in ethanol 96% (v/v)was also prepared; 0.5mL of the
cocrystal and ascorbic acid solutions, were each added to a 2.5mL
diluted stock solution of DPPH (2mL ethanol 96% (v/v)+ 0.5mL
DPPH 1mM). The mixture was then analyzed using an Uvi Line
9400 Spectrophotometer from SI Analytics at 516 nm for 20min.
Antioxidant activity was calculated using the
following equation:
AOA (%) = 100−
A516 (sample)
A516 (DPPH)
· 100 (5)
where:
AOA= antioxidant activity [%];
A516(sample)= absorbance of the sample measured at 516 nm at
a specific time;
A516(DPPH)= absorbance of the standard solution measured at
516 nm (without sample).
Cell Culture
HaCat (immortalized human keratinocytes), B164A5, and B16F0
(murine melanoma) cells were cultured in specific culture
medium–Dulbecco’s modified Eagle Medium (DMEM) with
high glucose (4.5 g L−1), L-glutamine and sodium bicarbonate,
supplemented with 100U mL−1 penicillin, 100 µg mL−1
streptomycin, and 10% fetal bovine serum (FBS). The number
of cells used in the experiments was determined in the presence
of Trypan blue using a Neubauer counting chamber (Coricovac
et al., 2017). HaCat and B16F0 cells were purchased from ATCC
(American Type Cell Collection) and B164A5 from Sigma-
Aldrich Chemie GmbH (Munich, Germany).
Human breast cancer (MCF-7, MDA-MB-231) and cervical
(HeLa) cell lines were purchased from European Collection of
Cell Cultures (Salisbury, UK). The cells were grown in Eagle’s
Minimum Essential Medium (EMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 1% non-essential
aminoacids, and 1% antibiotic-antimycotic mixture. All media
and supplements were obtained from Lonza Group Ltd. (Basel,
Switzerland). The cells were cultured in a humidified atmosphere
with 5% CO2 at 37◦C and were passaged at every two-three days.
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Determination of Cell Viability
The antiproliferative activities of the tested substances were
determined by standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Mosmann, 1984) and Alamar
blue assays. MTT: briefly, cells were plated into 96-well plates at
a density of 5,000 cells/well and pre-incubated overnight. After
incubation for 72 h with test compounds (BA+VitC cocrystal−3,
10, and 30µM), 20 µl of MTT solution was added and the
plates were incubated for another 4 h. The formed formazan
crystals were dissolved in 100 µl dimethyl sulfoxide and the
absorbance was determined at 545 nm.Wells with untreated cells
were utilized as control.
Alamar blue: The cells (1 × 104/200 µL medium/well) were
seeded in a 96-well plate and allowed to attach. After proper
confluence was reached, cells were incubated with different
concentrations (3, 10, and 30µM) of the BA+VitC cocrystal for
48 and 72 h. After the incubation period, the Alamar blue reagent
was added to each well (20 µL/well). The plates were incubated
for 3 h at 37◦C and the absorbance of each well was measured
using a xMark
TM
Microplate Spectrophotometer (Biorad) at 570
and 600 nm (reference) wavelengths. Cell viability was calculated
according to the formula described in our previous articles
(Soica et al., 2014b).
For both assays, MTT and Alamar Blue, DMSO (dimethyl
sulfoxide) was used as negative control. Even at the highest
concentration tested−30µM, the percentage of DMSO in the
growth medium was 0.03%, percentage that is considered non-
toxic for cells.
RESULTS AND DISCUSSIONS
Cocrystallization emerged as a successful procedure to modulate
the properties of solid active ingredients for the purpose of
improving drug delivery as well as drug manufacture; cocrystals
not only provide optimized physicochemical (i.e., solubility,
stability) and mechanical properties of the active drugs but
they also offer the possibility of combined therapies that come
along with intellectual property opportunities (Sun, 2012). In
addition, multidrug cocrystals may exhibit synergistic or additive
pharmacological effects. The design of possible cocrystals
involves the evaluation of potential non-covalent and non-
ionic intermolecular interactions between two or several active
ingredients; in general, cocrystal formers bear functional groups
that have the ability to form hydrogen bonds (Du et al., 2016).
Betulinic acid was identified as a very promising anticancer
agent and included in the Rapid Access to Intervention
Development (RAID) NCI program; however, its low water
solubility and permeability cause a poor bioavailability which,
despite its oral activity, imposes the necessity of large oral
doses (Godugu et al., 2014). BA solubility and permeability
properties may assimilate it as a BCS class IV compound
which generally does not reach market development (Chavda
et al., 2010). Previous studies reported various attempts to solve
BA physicochemical and pharmacokinetic drawbacks through
specific formulations: (1) cyclodextrin complexation (Soica et al.,
2014a), (2) nanoemulsion (Dehelean et al., 2013), (3) liposomes
(Mullauer et al., 2011), carbon nanotubes (Tan et al., 2014), (4)
polymer micelles (Das et al., 2016), or conjugates (Lomkova
et al., 2016). However, such formulations can be problematic
in terms of large scale production as well as storage (Sanphui
et al., 2015); therefore, crystal engineering might offer a superior
formulation alternative.
In designing potential cocrystals, a key point is the possibility
of intermolecular interactions between components, in particular
hydrogen bonds, that may trigger the molecular assembly and
determine the supramolecular architecture (Venugopalaiah et al.,
2016). The formation of a cocrystal depends upon the existence of
a coformer that dramatically influences the cocrystal properties,
mainly solubility, and dissolution (Tomaszewska et al., 2013).
To date, the selection of a suitable coformer is based on several
predictive criteria (Schultheiss and Newman, 2009); however, the
formation of a real cocrystal can be validated only through valid
experimental procedures. The most frequently used coformers
are compounds bearing functional groups such as carboxyle,
amide, hydroxyle, or amino groups (Jain et al., 2015). We assume
that this new compound BA+VitC in isopropanol monosolvate
can be linked together by the carboxylic bond.
Vitamin C was previously involved as coformer in
the formation of cocrystals (Kovac-Besovic´ et al., 2009;
Meepripruk et al., 2016); moreover, its antioxidant activity could
synergistically combine with the intrinsic antioxidant effect
of BA thus leading to a more soluble and higher biologically
active cocrystal. Another key element in cocrystallization is the
selection of solvents which depends on the solubility of both
drug and coformer and strongly influences the stoichiometry of
the resulting cocrystal (Leyssens et al., 2014).
Gas Phase ab initio DFT Calculations for
BA-VitC Cocrystal Formation
Calculated site pairing energy values for the pure forms of the
two structures and the expected cocrystal (1:1 ratio) are depicted
in Table 1. The obtained 1E value (−1.79 kJ/mol) suggests
that in the new cocrystal more favorable interactions may be
formed. Other previously reported 1E values for confirmed
1:1 ratio cocrystals, such as: caffeine:acetic acid (1E=−1),
caffeine:adipic acid (1E = −3), caffeine:sulfacetamide
(1E=−2), caffeine:sulfaproxyline (1E = −1) (Musumeci
et al., 2011), fall in the same range as our reported value. We can
therefore conclude that a BA-VitC 1:1 ratio cocrystal was formed
as a result of our crystallization process.
TABLE 1 | Calculated site pairing energy values for the pure forms of the two
structures and the expected cocrystal (1:1 ratio).
Compound Calculated site pairing energy
–αiβj (kj/mol)
Calculated 1E
(kj/mol)
VitC −22.76
BA −20.71 −1.79
VitC+BA proposed
cocrystal (1:1)
−45.26
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FIGURE 1 | SEM images of BA+VitC cocrystals (A), pure BA (B), pure VitC (C).
Scanning Electron Microscopy (SEM)
Analysis
SEM images of pure BA, pure VitC, and of their 1:1
cocrystal resulted from isopropanol solution are depicted in
Figure 1. The scanning electron microscopy images show
morphological differences between the pure ingredients and their
cocrystallization product, thus indicating the formation of a new
compound, formed through layer by layer deposition.
X-Ray Powder Diffraction Pattern
In order to provide an exhaustive structural characterization
at atomic level, a single crystal structure would be needed;
however, this single crystal might not be representative for the
polycrystalline product used as source. Moreover, single crystal
analysis requires a large enough and flawless crystal which is
difficult to achieve. In light of these facts, the more readily
available X-ray powder diffraction pattern (XRPD) is generally
used to assess a powder crystalline material in terms of crystal
structure, chemical composition, and physical properties.
The XRPD spectra forBA, VitC, and 1:1 BA+VitC cocrystal,
respectively, are presented in Figure 2. The BA+VitC profile
exhibits significant differences as compared to the ones recorded
for the pure compounds, thus suggesting the formation of
the cocrystal; in case of a simple physical mixture, the XRPD
spectrum of the sample would be the sum of the diffraction peaks
recorded for the pure compounds (BA and VitC) lacking any new
diffraction pattern.
The new formed peaks of the BA+VitC cocrystals are present
at 2θ, the most intense peaks are depicted at the following values:
5.04/8.82/8.94/9.86.The XRPD of the pure compounds revealed
the existence of crystal lattices; in the cocrystal diffractogram,
the peaks of starting materials are absent thus indicating
the formation of a new crystalline phase and supporting the
formation of an actual cocrystal.
Rietveld refinement of experimental XRPD pattern
corresponding to the proposed BA+VitC cocrystal is depicted in
Figure 3. The values obtained as a result of quantitative analysis
indicate the following composition, BA weight (%): 64.2742
and VitC weight (%) 35.72522, although calculated analysis
parameters such as the GOF (goodness of fit) = 2.24%, Rwp =
11.24%, and Rexp = 4.65% are slightly above the values that
ascertain a good fit, as indicated by the software developer.
Nevertheless, the refined profile, calculated according to the
corresponding data of the two phases, as seen in Figure 3,
shows a visual overall good fit. The high values of the analysis
parameters, mentioned above and a visual analysis of the refined
profile line, revealing that some peaks are not well-fitted, could
indicate polycrystalline forms (excess crystal forms of the
components) present in the analyzed powder. Taking all of this
in consideration and the fact that there is little crystallographic
structural information regarding the two phases (BA and VitC),
for obtaining a better fit, we can conclude that the formation of
the cocrystal was achieved but proposing a structure for the new
cocrystal is very difficult and it will constitute a research purpose
for future studies.
Differential Scanning Calorimetry (DSC)
Analysis
DSC is a thermal analysis that quantifies the difference between
the heat amounts required to increase the temperature of the
analyzed sample and the reference, respectively, as a function of
temperature or time.
Characteristic and comparable thermograms were recorded
for both pure ingredients BA and VitC and for their cocrystal as
well. The DSC curves for BA, VitC, and BA+VitC cocrystal are
presented in Figure 4.
For BA two small endothermic peaks at 241.23 and 255.56◦C
and a strong endothermic peak at 313.63◦C can be noticed,
corresponding to the melting of the compound accompanied
by decomposition. For VitC a sharp endothermic peak is
present around 192.8◦C, attributed to the melting point of the
compound, followed by a small exothermic peak correlated with
the beginning of chemical degradation. For BA+VitC cocrystal:
3 endothermic peaks appear at 150.85, 173.17, and 186.14◦C,
respectively, followed by an exothermic process that may indicate
the formation of a new structure that starts to decompose at
291.39◦C; the process is finished above 300◦C. The W-shaped
thermogram (Yamashita et al., 2013; Stoler and Warner, 2015)
such as the one obtained for BA+VitC proved to be characteristic
for the cocrystals, different from the V-shaped specific for the
eutectic mixtures.
Fourier-Transform Infra-Red Spectroscopy
(FT-IR) Analysis
The FTIR spectra of the analyzed samples (Figure 5) reveal the
binary adduct formation between the components, by the shifting
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FIGURE 2 | XRPD spectra for BA, VitC, and BA+VitC cocrystal.
FIGURE 3 | Experimental XRPD pattern of proposed BA+VitC cocrystal
compared with Rietveld refined profile (red continuous line).
of bands from the crystal to lower or higher wavenumbers,
outside the range of ±5 cm−1. At high wavenumbers (spectral
range 3,600–2,500 cm−1), the stretching of simple bonds such as
O-H and C-H occurs. The broad band observed in the spectral
range 3,600–3,400 cm−1 reveal the presence of intermolecular
bonds, both in the case of pure BA, as in the case of the
BA+VitC cocrystal. This observation leads to the conclusion that
the formation of cocrystal occurs by hydrogen bonding.
The fingerprint region (spectral range 1,800–400 cm−1)
contains numerous bands, due to the complex mode of vibration
FIGURE 4 | DSC curves forBA, VitC, and BA+VitC.
for both precursors (BA and VitC), as well as for the cocrystal.
The modification of wavenumbers in this region is not easy
to asses and is generally associated with bending and wagging
(Schrader, 2008; Kovac-Besovic´ et al., 2009; Ahmad et al.,
2010; Joshi et al., 2013; Wang et al., 2014; Stoler and Warner,
2015; Zhang et al., 2015; Yang et al., 2016). The experimental
wavenumbers, expressed in cm−1, obtained in this study for
the cocrystal of BA+VitC/VitC/BA present absorption bands at:
748/756/789 that could be assigned to C-C bending vibration;
883/-/884 assigned to = CH2 wagging vibration; 916/821/918
attributed to C-H and C-C bending vibration. The bands located
at 982/869/983, 1010/989/1009, -/1078/1083, 1131/ 1143/ 1106
can be assigned to C-H, C-C and C-O bending vibrations.
At 1235/1222/1239 is the band corresponding to C-H, C-C
and O-H bending vibration. The bending vibration for C-
H2 is located at -/1274/1298 and for C-CH3 is located at
1374/1388/1376. The bending vibration of C-H2 in the ring is
present at 1453/1498/1450. The band present on the spectra
at 1642/-/1643 correspond to C=C stretching vibration. At
1685/1679/1685 is the band that could be assigned to C=O
stretching vibration in the ring. Vitamin C also presents
a band at 1753 that can be attributed to C=O stretching
vibration. C-H stretching vibration is present at 2869 for
BA+VitC and at 2868 for BA. At 2942/2916/2940 is present
the band that can be assigned to –CH2 stretching vibration.
The band characteristic for the O-H stretching vibrations are
3075/3219/3203 and 3437/3315/3471.
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FIGURE 5 | FTIR spectra for BA, VitC, and BA+VitC.
The Antioxidant Activity (AOA) Assessment
The AOA of the BA+VitC cocrystal and ascorbic acid, used
as standard are exhibited in Figure 6. One can notice that the
cocrystal shows as lightly increased AOA compared to that of
pure ascorbic acid.
It can be assumed that the BA used in the preparation of
the cocrystal has contributed to the reaction with DPPH thus
leading to a higher AOA value compared to the one recorded for
ascorbic acid. One can notice that values vary by 2% (ascorbic
acid−95%, cocrystal−97%). The antioxidant activity of vitamin
C was preserved in the 1:1 combination with BA and even
increased by the presence of the triterpenic acid; however, the
slight increase in antioxidant effect can be due to the intrinsic
antioxidant activity of BA itself. Therefore, we can state at most
that the antioxidant activities of both compounds wasmaintained
in their cocrystal.
In vitro Analysis
The cytotoxicity assessment of BA+VitC cocrystal solution
was performed on healthy (HaCaT–immortalized human
keratinocytes) and cancer (B16F10, B164A5–murine melanoma;
MCF-7, MDA-MB-231–human breast carcinoma and HeLa–
human cervix carcinoma) cell lines using three different
concentrations−3, 10, and 30µM by means of both MTT and
Alamar blue assays. DMSO had no impact on cells viability, the
inhibition values being similar with the ones obtained for control
cells (unstimulated).
FIGURE 6 | Recorded AOA of the BA+VitC cocrystal and ascorbic acid.
The stimulation of HaCaT cells with BA+VitC cocrystal at 3
and 10µM for 72 h did not reveal a significant cytotoxic effect,
the cellular inhibition being maintained below 10% (Figure 7A).
The lack of toxic effects of betulinic acid on normal cells
has been reported since the first research paper concerning
its anti-melanoma activity (Pisha et al., 1995) although the
respective paper analyzed its toxicity on in vivo animal models;
therefore, betulinic acid was used as scaffold for various chemical
derivatives with the purpose of preserving its good selectivity
index (Waechter et al., 2017). Our study revealed however a
rather significant cell inhibition (∼40%) for BA alone at 30µM
that is strongly attenuated by the presence of vitamin C, being
reduced at∼15%.
A significant cell inhibition was noted at the lowest
concentration (3µM) against HeLa cells (45%) for both BA and
BA+VitC (Figure 7C); the inhibition increased with the applied
dose for both samples thus presenting a dose-dependent profile:
70% cell inhibition at 10µMand∼100% cell inhibition at 30µM.
The inhibitory effect was virtually equal for BA and BA+VitC at
all concentrations.
Insignificant cell inhibition values were noted at 3µM against
MCF-7 and MDA-MB-231 cells (<10%) for BA and BA+VitC
(Figure 7C). At 10µM a 25% cell inhibition was reported for
BA alone against MCF-7 cells while the inhibitory activity
almost doubled for the cocrystal at the same concentration
thus indicating a strong antiproliferative activity induced by the
presence of VitC. When concentration increased at 30µM a total
cell inhibition was recorded for both BA and its cocrystal with
VitC; therefore, it can be stated that the cell inhibition profile
evolves in a dose-dependent manner.
Interestingly, the MDA-MB-231 cell line was moderately
sensitive to 10µM BA (25% cell inhibition) but did not react
to the same concentration of BA+VitC cocrystal, when cell
inhibition was practically null. The use of the highest tested
concentration, 30µM, induced an inhibitory activity of 60% for
BA alone while in the presence of VitC cell inhibition reached
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FIGURE 7 | In vitro cytotoxicity assessment of BA and BA+VitC cocrystal (3, 10, and 30µM) on immortalized human keratinocytes—HaCat (A); murine melanoma
cells–B16F0 and B164A5 (B); breast–MCF-7 and MDA-MB-231–and cervical–HeLa cancer cells (C), after 72 h stimulation, by the means of MTT assay. The results
are expressed as inhibition index (%) related to control cells (unstimulated). The data represent the mean values ± SD of three independent experiments performed in
triplicate. One-way ANOVA analysis was applied to determine the statistical differences followed by Tukey post-test (**p < 0.01; ***p < 0.001; ****p < 0.0001).
90% thus revealing a highly effective antiproliferative activity of
the cocrystal.
Gao et al. reported in 2017 an important inhibition of the
MDA-MB-231 cell line by various concentrations of betulinic
acid ranging between 10 and 160µM; however, in his study,
cellular viability only decreased to around 50% when 40µM
BA was used, due to ultrastructural and morphological changes
(Gao et al., 2018). In the current study, a similar cell inhibition
was caused by a lower concentration of BA (30µM) which
significantly improves, reaching 90% cell inhibition, when the
BA+VitC cocrystal was used. Our results are in line with
the ones reported by Weber et al. who determined the IC50
value of betulinic acid against MDA-MB-231 cells as 21.9µM
thus revealing a strong cytotoxic effect (Weber et al., 2014).
For HeLa cells, a 50% cellular viability was reported after
48 h stimulation with 30µM BA, with a time- and dose-
dependent inhibitory activity and an IC50 value of 30.42
± 2.39µM (Xu et al., 2017). The same group of authors
reported in 2014 a 50% viability of HeLa cells after 48 h
stimulation with 50µM BA (Xu et al., 2014). By comparison,
our results showed similar inhibition percentages at much
lower concentrations (3–10µM) while at 30µM the cellular
inhibition was almost complete both for BA and its cocrystal with
VitC. An important antiproliferative activity was also previously
reported by our group for BA against MCF-7 and HeLa cell
lines (Soica et al., 2012).
In the case of murine melanoma cells–B16F10 (Figure 7B),
the lowest concentration of both samples (3µM) induced a
negligible cell inhibition, whereas the higher concentrations−10
and 30 µM–exerted significant cytotoxic effects, the highest
inhibition index being recorded after the 30µM stimulation
(around 50% for both samples); at 10µM, a stronger cytotoxic
activity was noted for BA+VitC cocrystal when compared to
BA alone. The cell inhibition activity followed a dose-dependent
profile. BA was previously reported as anti-melanoma agent
(Pisha et al., 1995) and was revealed to increase in a synergistic
manner the antitumor activity of vincristine in an in vitro/in vivo
study on B16F10 cells (Sawada et al., 2004); BA caused the arrest
of B16F10 melanoma cells in the G1 phase.
A visibly higher cytotoxic activity was recorded against
B164A5 murine melanoma cells after stimulation with BA+VitC
cocrystal as compared to BA alone, in all concentrations,
respectively; the cell inhibition activity evolved in a dose-
dependent manner. The highest inhibitory activity for BA alone
(20%) was recorded at its highest used concentration (30µM); in
a similar manner, the strongest cell inhibition was exhibited by
BA+VitC cocrystal at 30µM but the value of cell inhibition was
more than twice compared to BA alone (∼45%).
Our group reported in 2014 the cytotoxic activity of BA
against B164A5 cells leading to 50% cell viability at 10mM;
BA was solubilized by inclusion in octakis-[6-deoxy-6-(2-
sulfanyl ethanesulfonic acid)]-γ-CD (Soica et al., 2014a). By
Frontiers in Chemistry | www.frontiersin.org 8 February 2019 | Volume 7 | Article 92
Nicolov et al. Betulinic/Ascorbic Acid Cocrystals as Anti-cancer Agents
comparison, the current study reports a similar citotoxic activity
but using a much lower concentration of BA in the form of
its VitC cocrystal (30µM). The antimelanoma activity of BA
was also confirmed using the murine B16/C57BL6 melanoma
model (Soica et al., 2014a).
In terms of cytotoxic activity of vitamin C, the reported data
is controversial. Most papers revealed the potentiation of the
cytotoxic effects of various drugs following combination with
vitamin C. Bober et al. reported in 2016 the up- and down-
regulation of numerous proteins (229) by the combination of
doxorubicin and vitamin C that resulted in the augmentation
of the antiproliferative effect of doxorubicin (Bober et al.,
2017). Guerriero et al. tested the cytotoxic effect of vitamin
C, mitoxantrone, and their combination, respectively, against
MCF-7and MDA-MB-231 breast cancer cells; they noticed a
dose-dependent cell inhibition on both cell lines for both tested
compounds while their combination provided a synergistic
effect and allowed lower chemotherapic doses (Guerriero
et al., 2014). The association of vitamin C with quercetine
exerted antiproliferative effects against several breast cancer
cell lines (MDA-MB-231, MCF-7, MDA-MB-468) through the
induction of Nrf2-mediated oxidative stress in cancer cells in
a synergistic manner as well (Mostafavi-Pour et al., 2017); the
combination of vitamin C and quercetine with doxorubicin
and paclitaxel caused a dramatical decrease of the IC50 of
drugs and induced apoptosis in early stages (Ramezani et al.,
2017). The administration of non-cytotoxic doses of vitamin C
increased the chemotherapic response and apoptosis of HeLa
cells treated with etoposide and cisplatin (Reddy et al., 2001).
High concentrations of ascorbic acid (7–10mM) administered
intravenously were found to induce apoptosis of HeLa cells
through the intrinsic and extrinsic pathways (Roberts et al.,
2015); also, high doses of vitamin C inhibited energy metabolism
inMCF-7 cancer cells through NAD depletion, thus inducing cell
death (Uetaki et al., 2015). In counterpart, vitamin C was found
to dose-dependently protect MCF-7 cancer cells against lipid
peroxidation caused by tamoxifen thus causing a dose-dependent
attenuation of cytotoxicity and diminishing the therapeutic
response (Subramani et al., 2014).
Taking into account all these data, we can state that the
cocrystallization of BA with vitamin C significantly improved the
cytotoxic effect of BA against the tested tumor cell lines while
preserving its good selectivity index. In part, we can assume that
the increase of the biological activity of BA could be due to the
intrinsic cytotoxic activity of vitamin C. However, the existing
reports that incriminate vitamin C as cancer cell protector cast
a shadow of doubt upon this assumption; in this regard, we may
assume that vitamin C exhibited a protective effect on the MDA-
MB-231 cancer cells when the 10µM concentration was used,
concentration at which BA alone caused a 25% cell inhibition.
The mechanism behind this reported protective activity is yet to
be investigated.
In the meantime, an important parameter in the investigation
of poorly soluble drugs such as BA is solubility, parameter that
can be greatly improved through cocrystallization (Qiao et al.,
2011). As an example, the apparent solubility of vitamin K3
was greatly increased by cocrystallization with naphtoic acids
and sulfamerazine (Zhu et al., 2015). Vitamin C was successfully
employed as coformer in the cocrystallization of acyclovir
for the purpose of improving the latter’s water solubility and
bioavailability (Meepripruk et al., 2016). Therefore, we presume
that the experimental data reported here that revealed a very
strong cytotoxic effect of BA+VitC cocrystals as compared to
previously and currently reported data for BA alone are partially
due to an increased water solubility of BA as a result of vitamin
C cocrystallization; moreover, the presence of vitamin C as
coformer may lead to an optimized bioavailability, subject that
needs however further investigations.
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